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To evaluate the efficacy and safety of TNF-a blockers for ulcerative colitis. A systematic
search for randomized controlled trials (RCTs) of TNF-a blockers for treatment of ulcerative
colitis (UC) were performed in PubMed, Web of Science, Embase and cochrane clinical trial.
We estimated Pooled estimates of the odds ratio (OR) and relevant 95% confidence interval
(CI) using fixed effects model or random effects model as appropriate. Heterogeneity,
publication bias, and subgroup analyses were conducted. Nine randomized controlled
studies met the selection criteria with a total of 2518 patients. Five studies compared
Infliximab with placebo. Two studies compared Infliximab to corticosteroids. Two studies
compared Adalimumab to placebo. One study compared subcutaneous golimumab to
placebo. Short-term response, short-term remission, long-term remission and mucosal
healing were better in the TNF-a blocker group than in the control group (p < 0.05). TNF-a
blockers decreased the colectomy rate and serious adverse reactions (p < 0.05). The TNF-a
blockers were superior to controls in achieving short-term clinical response/remission,
long-term remission and mucosal healing and decreased the colectomy rate and serious
adverse reactions.
Copyright © 2014, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.  Open access under CC BY-NC-ND license.1. Introduction
Ulcerative colitis (UC) is a chronic inflammatory disorder of
the gastrointestinal tract with an unknown etiology, and the
incidence of UC has markedly increased in Eastern Europe,roenterology, Shanghai Ea
m (P. Zheng).
ministration, Taiwan. PublSouth America, and Asia [1]. The clinical course of UC is
characterized by periods of remission and relapse, with acute
inflammatory exacerbations of disease activity which, when
severe, are potentially life-threatening. The standard initial
management of these inflammatory exacerbations includesst Hospital of Tongji University, 150 Jimo Road, Shanghai 200120,
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
j o u r n a l o f f o o d and d r u g an a l y s i s 2 3 ( 2 0 1 5 ) 1e1 02high dose intravenous glucocorticosteroids in the first
instance; however, this strategy may be unsuccessful in up to
50% of patients. Immunomodulating drugs such as azathio-
prine, although effective in maintaining remission, act too
slowly to be of use in the acute setting [2]. With the develop-
ment of molecular biology and immunology, the UC patho-
genesis has been further studied. It has been reported that
there is high tumor necrosis factor-alpha (TNF-a) expression
in blood, colonic tissue, and stool of patients with UC [3]. TNF-
a, a proinflammatory cytokine, is already known to play an
important role in the pathogenesis of Crohn's disease (CD),
and anti-TNF therapy has been demonstrated to be useful in
moderate to severe CD [4,5]. It can inducemucosal healing and
has been shown to have a high steroid-sparing efficacy in
active CD [6]. In UC, however, the results have been conflict-
ing. There is insufficient evidence to advocate using anti-TNF
as a first-line agent for UC patients with mild or moderate to
severe disease. The efficacy of anti-TNF in UC has been
investigated by a limited number of randomized controlled
trials (RCTs) and results from these earlier studies were
equivocal and ambiguous [7,8]. Two previous meta-analyses
of RCTs have evaluated the efficacy of TNF-a blockers
including adalimumab for induction or maintenance of clin-
ical remission in UC [9,10]. However, two further trials have
been reported since these meta-analysis [11,12], and one
meta-analysis showed greater heterogeneity between TNF-a
blocker groups [10]. In order to provide a comprehensive up-
to-date therapeutic effects and safety of TNF-a blockers in
the treatment of moderate and severe UC, RCTs published in
recent years were meta-analyzed.2. Methods
2.1. Literature search strategy
We conducted a systematic search for clinical trials in
PubMed, Web of Science, Embase, and Cochrane Clinical Tri-
als from 1990 to May 2013 using the following keywords:
tumor necrosis factor, anti-TNF, TNF, infliximab, adalimu-
mab, golimumab, certolizumab pegol, UC, randomized,
random, randomly, and controlled trial. The reference lists of
eligible studies and review articles were also checked manu-
ally to identify other relevant publications. The primary au-
thors were contacted for missing data. All studies included in
this meta-analysis were written in English.2.2. Inclusion and exclusion criteria
Inclusion criteria were (1) RCTs; (2) a study design that
included a TNF-a blocker group and a placebo, glucocorticoid,
or other drug control group; and (3) assessment of thera-
peutic effects including one or more parameters such a
short-term response, short-term remission, long-term relief,
mucosal healing, colectomy rate, and serious adverse re-
actions. We excluded studies not accessible to full research
data. Reviews, case reports, letters, and editorials were
excluded. Articles about children or pregnant women were
also excluded.2.3. Data extraction
Data were abstracted by two independent investigators (Y.-
N.S.. and P.Z.). Each article was comprehensively scrutinized
to determine whether it met the predetermined inclusion
and exclusion criteria. Each investigator abstracted the
following data from each report: first author, year of publi-
cation, total number of patients, control group, duration, and
total Jadad scores. If the results obtained from the articles
were different, disagreements were resolved by analyzing
the data.
2.4. Quality evaluation
The methodological quality of included trials was assessed
using the Jadad score, which judges descriptions of random-
ization, blinding, and dropouts (withdrawals) in trials [13]. The
quality scales ranged from 0 points to 5 points, with a low-
quality report scoring  2 points and a high-quality report
scoring at least 3 points [14].
2.5. Statistical analysis
Pooled estimates of the odds ratio (OR) and relevant 95%
confidence interval (CI) were obtained by using a random-
effects model or a fixed-effects model. Heterogeneity across
trials was evaluated with the I2 statistic. The I2 values ranged
from 0% to 100%: 0% suggested no observed heterogeneity,
25e49% suggested low, 50e74% moderate, and 75% high
heterogeneity [15]. A p value < 0.1 was defined as a significant
heterogeneity. If heterogeneity existed, a random-effects
model was used to assess the overall estimate. Otherwise, a
fixed-effects model was chosen. Subgroup analysis was per-
formed to account for heterogeneity.3. Results
3.1. Study selection
Our search strategy yielded 5771 citations (Fig. 1).We retrieved
41 citations for a detailed evaluation, of which 32 were
excluded.Nine studiesdfour studies that compared infliximab
to placebo, two studies that compared infliximab to cortico-
steroids (1 study to oral corticosteroids and the other study to
intravenous corticosteroids), two studies that compared ada-
limumab to placebo, and one that compared golimumab to
placebodmet the inclusion criteria [7,8,11,12,16e20].
3.2. Characteristics of the studies
The basic characteristics of the studies are reported in Table 1.
A total of 2518 patients were enrolled. Five studies that
compared infliximab with placebo included 539 infliximab,
and 288 placebo. Two studies compared infliximab to corti-
costeroids and two studies compared adalimumab to placebo
to evaluate the efficacy of adalimumab in induction and
maintenance of clinical remission in patients with moderate-
to-severe UC. In Reinisch et al's study [16], there were two
groups (ADA 160/80 and ADA 80/40). One study compared
Fig. 1 e Literature search strategy.
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characteristics of the studies included in the meta-analysis.
3.3. Short-term clinical response and remission
Six RCT papers reported the short-time response (2e8 weeks)
and remission. The heterogeneity test indicated that
c2 ¼ 22.39 and p ¼ 0.002, demonstrating heterogeneity.
Therefore, the random-effectsmodel was adopted, and the OR
value was 2.34 (95% CI, 1.66e3.29; p < 0.00001; Fig. 2). To
investigate the factors that may result in the heterogeneity,
we performed subgroup analyses based on the TNF-a blocker
groups. In the infliximab group, there were three RCT papers
that investigated the short-term response. The heterogeneity
test indicated that c2¼ 2.71 and p¼ 0.44, and the OR valuewas
3.87 (95% CI, 2.80e5.34; p < 0.0001). There was no statistical
heterogeneity. In the adalimumab group, there were only two
studies, comprising 1014 patients. The heterogeneity test
indicated that c2¼ 1.65 and p¼ 0.44, and the OR valuewas 1.63
(95% CI, 1.27e2.09). There was no statistical heterogeneity. In
the golimumab group, golimumab showed betterTable 1 e Basic characteristics of studies included in meta-ana
First author Published
year
Cases
(n)
Control grou
Sands [7] 2001 11 placebo
Probert [8] 2003 43 Placebo
Rutgeerts (ACT1) [17] 2005 364 Placebo
Rutgeerts (ACT2) [17] 2005 364 Placebo
Jarnerot [18] 2005 45 Placebo
Armuzzi [20] 2004 20 Methylprednisol
Ochsenkuhn [19] 2004 13 Prednisolone
Reinisch [16] 2011 390 Placebo
Sandborn [11] 2012 494 Placebo
Sandborn [12] 2013 774 n Placebo
NR ¼ no report; SC ¼ subcutaneous; TNF-a ¼ tumor necrosis factor-alph
a In Phase 2 of this study, the doseeresponse of SC golimumab induct
baseline to Week 6. So the actual number of patients was 774.performance than placebo for short-term response (Fig. 3).
There was a substantial heterogeneity among different TNF-a
blocker groups, therefore, we think that was the primary
reason for the heterogeneity. We did not conduct a meta-
regression analysis to explore the factors causing heteroge-
neity. But in the overall analysis, the results of the short-term
response (2e8 weeks) of these RCTs were consistent. There-
fore, the TNF-a blockers were effective for the rapid induction
of response.
Short-term remission (2e8 weeks) was reported in six
RCT papers. The heterogeneity test indicated that c2 ¼ 16.38
and p ¼ 0.01, demonstrating heterogeneity. Therefore, a
random-effects model was adopted, and the OR value was
2.49 (95% CI, 1.60e3.89; Fig. 4). In clinical practice, one of the
therapeutic goals for a new biological agent is the rapid in-
duction of response or remission. But in those six RCT pa-
pers, the heterogeneity showed significant differences
between the TNF-a blocker groups. The factor that caused
the heterogeneity may be that almost every RCT uses a
unique clinical or endoscopic index. Moreover, the defini-
tions of remission or improvement differ across the studies.
This limits the conclusion of studies that compare RCTs in
UC patients. For example, in the work of Rutgeerts et al [17]
(ACT1), clinical remission was defined as a total Mayo score
of  2 points, with no individual subscore exceeding 1 point.
But in the paper of Probert et al [8], clinical remission was
defined as ulcerative colitis symptom score (UCSS) < 2, and
sigmoidoscopic remission was defined as a Baron score of 0.
In the overall analysis, however, the short-term remission
rate was significantly higher than that in the control group.
We did not conduct metaregression analysis to explore the
factors causing the heterogeneity.3.4. Long-term remission
Long-term remission (12 weekse10.9 months) was reported in
five RCT papers. The heterogeneity test indicated that
c2¼ 4.71 and p¼ 0.45, demonstrating homogeneity. Therefore,
a fixed-effects model was adopted, and the OR value was 2.71
(95% CI, 1.97e3.73) (Fig. 5). So the TNF-a blockers performed
better than the control groups in terms of long-term
remission.lysis.a
p Duration TNF-a blocker
group
Total Jadad scorea
10 wk Infliximab 4
6 wk Infliximab 5
54 wk Infliximab 5
30 wk Infliximab 5
6 mo Infliximab 5
one NR Infliximab 3
13 wk Infliximab 3
8 wk Adalimumab 5
52 wk Adalimumab 5
6 wk Golimumab 5
a.
ion therapy was assessed based on the change in Mayo score from
Table 2 e Main characteristics of studies included in meta-analysis.
First author Year Outcomes of different studies
Sands [7] 2001 Primary endpoint was clinical response defined as a modified Truelove and
Witts score < 10 and a 5-point reduction compared with baseline at 2 wk.
Probert [8] 2003 Primary end points were clinical remission at Week 6: clinical remission
defined as UCSS < 2 and sigmoidoscopic remission as a Baron score of 0.
Rutgeerts (ACT1 and ACT2) [17] 2005 The primary end point was a clinical response at Week 8. Clinical response
was defined as a decrease from baseline in the total Mayo score of at least 3
points and at least 30 percent, with an accompanying decrease in the
subscore for rectal bleeding of at least 1 point or an absolute subscore for
rectal bleeding of 0 or 1. Clinical remission was defined as a total Mayo score
of 2 points or lower, with no individual subscore exceeding 1 point. Mucosal
healing was defined as an absolute subscore for endoscopy of 0 or 1.
Jarnerot [18] 2005 The primary end point was colectomy or death within 90 d after infusion.
Secondary end points were clinical remission according to the Seo index
and endoscopic remission 1 and 3 mo after the infliximab/placebo infusion.
Armuzzi [20] 2004 Primary outcome was remission defined as disease activity index (DAI) < 3
within 2 wk.
Ochsenkuhn [19] 2004 Therapy success was defined as clinical response in terms of a decrease of >
5 points from baseline score (modified Truelove and Witts activity score)
and to < 10 points total after 3 wk as well as after 13 wk, and no need to start
or increase high-dose prednisolone dosage or to perform colectomy. A
secondary endpoint was the achievement of remission after 13 wk.
Reinisch [16] 2011 The primary efficacy endpoint was clinical remission (Mayo score  2 with
no individual subscore > 1) at Week 8.
Sandborn [11] 2012 Primary end points were remission at Week 8 and Week 52.
Sandborn [12] 2013 The primary endpoint was clinical response at Week 6, and secondary
endpoints were clinical remission, mucosal healing, and IBDQ change from
baseline, all at Week 6.
IBDQ ¼ The Inflammatory Bowel Disease Questionnaire (IBDQ); UCSS ¼ ulcerative colitis symptom score (UCSS).
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The therapeutic goals in UC had evolved to include mucosal
healing as a measure of treatment efficacy. Mucosal healing
was reported in seven RCT papers. The heterogeneity test
indicated that c2 ¼ 26.88 and p ¼ 0.0007, demonstrating
heterogeneity. Therefore, a random-effects model was
adopted, and the OR value was 1.68 (95% CI, 1.18e2.40;
Fig. 6). So we performed subgroup analysis based on the
TNF-a blocker groups (Fig. 7). In the infliximab group, there
are four RCT papers that investigated the mucosal healing.
The heterogeneity test indicated that c2 ¼ 6.11 and p ¼ 0.19,
and the OR value was 2.84 (95% CI, 2.09e3.86; p < 0.0001).
There was no statistical heterogeneity. InfliximabFig. 2 e The forest plot of short-term response to tumor necrosisperformed better than the control group in terms of mucosal
healing. In the adalimumab group, there were only two
studies. The heterogeneity test indicated that c2 ¼ 3.25 and
p ¼ 0.20, and the OR value was 1.23 (95% CI, 0.96e1.59).
There was no statistical heterogeneity. However, adalimu-
mab did not perform better than the control group in terms
of mucosal healing, a result that is different from that of
adalimumab for CD treatment [21]. There was only one
paper about golimumab, and golimumab performed signifi-
cantly better than the control group for mucosal healing.
So the hterogeneity may be a result of the different
TNF-a blockers have been used. In the overall analysis,
however, TNF-a blockers were superior to placebo in
mucosal healing.factor-alpha blockers for the treatment of ulcerative colitis.
Fig. 3 e The short-term response to tumor necrosis factor-alpha blockers in subgroup patients.
Fig. 4 e The forest plot of short-term remission to tumor necrosis factor-alpha blockers for the treatment of ulcerative colitis.
Fig. 5 e The forest plot of long-term remission to tumor necrosis factor-alpha blockers for the treatment of ulcerative colitis.
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Fig. 6 e The forest plot of mucosal healing rate following the use of tumor necrosis factor-alpha blockers for the treatment of
ulcerative colitis.
Fig. 7 e The mucosal healing rate following the use of tumor necrosis factor-alpha blockers in subgroup patients.
Fig. 8 e The forest plot of serious adverse reactions with regard to the use of tumor necrosis factor-alpha blockers for the
treatment of ulcerative colitis.
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Fig. 9 e The forest plot of colectomy rate following the use of tumor necrosis factor-alpha blockers for the treatment of
ulcerative colitis.
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Six papers have reported the safety of the TNF-a blockers.
Serious adverse events, which qualified as life-threatening or
severe, were recorded. The serious adverse events included
abdominal pain, nausea, arthralgia and upper respiratory
tract infection, and malignant tumors. The heterogeneity test
indicated that c2 ¼ 9.43 and p ¼ 0.22, demonstrating homo-
geneity. Therefore, a fixed-effectsmodel was adopted, and the
OR value was 0.69 (95% CI, 0.53e0.88; Fig. 8). There was no
apparent relationship between the treatment using TNF-a
blockers and the incidences of all treatment-emergent
adverse events. Therefore, the TNF-a blockers did not in-
crease the risk of serious adverse events.
3.7. Colectomy
Colectomy was reported in four RCT papers. The heteroge-
neity test indicated that c2 ¼ 2.15 and p ¼ 0.54, demonstrating
homogeneity. Therefore a fixed-effects model was adopted,
and the OR valuewas 0.32 (95%CI, 0.18e0.58; p¼ 0.0001; Fig. 9).
Therefore, TNF-a blockers can reduce colectomy rates when
compared with the control group, but the risk of colectomy, in
the long term, is not modified. Moreover, there were only two
studies that evaluated the long-term colectomy rate [22,23];
here, the heterogeneity test indicated c2 ¼ 3.77 and p ¼ 0.05,
demonstrating heterogeneity (Fig. 10).
3.8. Publication bias
A funnel plot was used to assess the presence of publication
and other reporting biases by plotting the standard error
against the log OR (Fig. 11). The shape of the funnel plot was
symmetrical, indicating no significant publication bias. AllFig. 10 e The forest plot of long-term colectomy rate following
treatment of ulcerative colitis.analyses were performed using the software Review Manager
5.0 (Cochrane Collaboration, Oxford, UK).
In the TNF-a blocker and control groups, all funnel plots of
short-term response, short-term remission, long-term
remission, mucosal healing, severe adverse reactions, and
colectomy rate were roughly symmetrical, suggesting the
absence of publication bias. But in the analysis of each
parameter, only a small number of studies were included, so
publication bias was of concern.4. Discussion
UC is a chronic relapsing inflammatory disorder of the large
bowel, and the cause of the disorder is not known. The con-
dition is thought to arise fromdysregulation of both the innate
and adaptive immune systems, leading to an abnormal in-
flammatory response to commensal bacteria in a genetically
susceptible individual [24]. Cytokines, including proin-
flammatory cytokines and anti-inflammatory cytokines, play
an important role in regulating intestinal immunity [25]. The
cytokine profiles of CD and UC are usually different. CD is
associated with an overexpression of Th1-related proin-
flammatory cytokines, whereas the latter is associated with
an increased production of Th2-related inflammatory mole-
cules [26]. However, increased serum and colonic mucosa
concentrations of TNF-a have also been reported in patients
with UC, suggesting a possible role in the pathogenesis of the
disease [27,28]. Until recently, the management of UC con-
sisted of the stepwise use of mesalazine, corticosteroids, and
immunomodulators, or consideration of surgery [29,30]. In the
past decade, anti-TNF-a agents made an important contribu-
tion to the management of CD, especially in patients who
were refractory to conventional therapies. The role of TNF-athe use of tumor necrosis factor-alpha blockers for the
Fig. 11 e Assessment of publication bias using a funnel plot. Funnel plot analysis of the (A) short-term response, (B) short-
term remission, (C) long-term remission, (D) mucosal healing, (E) serious adverse events, and (F) colectomy between TNF-a
blocker groups and control groups.
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have yielded conflicting results.
Thereare several differences in the therapeuticmechanism
of various TNF-a blockers. Infliximab, an immunoglobulin (Ig)
G1 chimeric monoclonal antibody, binds with high affinity to
free and membrane-bound TNF-a, neutralizing its biological
activity [29]. In 2010, infliximab was the only biological agent
approved for the treatment of UC in the United States and
Europe [31]. Adalimumab is a fully human IgG1 monoclonal
antibody directed against TNF-a that inhibits the activity of
this cytokine by blocking the interaction of TNF-awith its p55
and p75 cell surface receptors. Adalimumab is approved in the
United States, Europe, and Japan for CD [32]. Recently, twoRCTs have demonstrated the ability of adalimumab to induce
clinical remission inpatientswithmoderate-to-severeUC, and
found that adalimumab might be an effective therapy for UC.
Golimumab represents another relatively new human mono-
clonal anti-TNF IgG1 antibody; it is a fully humanmonoclonal
antibody to TNF-a and is subcutaneously administered [33].
This drug has only been tested in active UC. Certolizumab
pegol is a more recently developed TNF-a antagonist with a
unique physical structure that may provide an alternative
tolerability profile to other TNF-a antagonists, and currently
approved in the US as a treatment for CD [34]. To date, no RCT
has compared the efficacy/safety of certolizumab with active
treatments for UC. There may be clinically important
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directly related to the structure of protein therapeutics and
may result in increased adverse effects and diminished effi-
cacy. Thus, adalimumab, golimumab, and certolizumab may
be safer andmore effective than infliximab because they have
weaker immunogenicity than infliximab.
The authors conducted a systematic review and meta-
analysis of the available published RCTs to examine the ef-
ficacy and safety of the TNF-a blockers in the treatment of
UC. A total of nine RCTs met the criteria and were included in
the meta-analysis, and the quality of many of these studies
was very high (Jadad score  3). Six of the included studies
compared infliximab with controls (4 compared infliximab
with placebo and 2 compared infliximab with corticoste-
roids), two studies compared adalimumab with placebo, and
one study compared golimumab with placebo. For the short-
term response and mucosal healing, we found that TNF-a
blockers were superior to controls, but heterogeneity across
studies was found. Exploring the sources of heterogeneity
using subgroup analysis, we found that the various TNF-a
blockers influenced the heterogeneity. Therefore, we
analyzed the effects in the subgroups. Heterogeneity was not
found in infliximab, adalimumab, and glimumab. The results
suggested that infliximab, adalimumab, and golimumab were
superior to placebo in achieving short-term response. For the
mucosal healing, however, adalimumab was not more
effective than placebo. For short-term remission (2e8 weeks),
the heterogeneity was significantly different between the
TNF-a blocker groups. The reason for this heterogeneity was
that different short-term remission measurements were
used. But in the overall analysis, TNF-a blockers performed
significantly better than the control group in terms of short-
term remission rate.
In this meta-analysis, long-term remission, serious
adverse reactions, and colectomy rate were also considered.
Overall, the TNF-a blockers did not increase the risk of death,
serious infections, or malignancy. And for long-term remis-
sion and colectomy rate, the TNF-a blockers were superior to
controls, and heterogeneity across studies had not been
found. However, whether TNF-a blockers can prevent colec-
tomy in the long term remains to be elucidated and will
require further long-term prospective studies.
In contrast to previous meta-analyses examining the effi-
cacy and safety TNF-a blockers for UC, the current analysis
included the findings from a recently published RCT reported
by Sandborn and colleagues [11], who first introduced goli-
mumab for the treatment of UC [12].
All papers selected for this study were high-quality RCTs
(Jadad score  3 points) and fulfilled the inclusion criteria.
However, our meta-analysis has several limitations. First,
there was only one RCT that compared the golimumab with
placebo. A second limitation is that all studies included in
this meta-analysis were written in English. Hence, it is
possible that we may have missed potentially relevant trials
from non-English language literature. Third, these data need
to be interpreted with caution because the patients in these
clinical trials might not be representative of patients seen in
clinical practice, and follow-up might not be sufficiently long
for some serious events such as malignancy (if they
occurred). Fourth, we did not perform metaregression toassess the factors that resulted in heterogeneity; we specif-
ically performed subgroup analyses on patients assigned to
various TNF-a blocker groups.5. Conclusion
In the past decade, infliximab has made an important
contribution to the management of UC, and it is the only
biological agent approved to treat patients with UC, but as
time goes by, more and more studies have found that
numerous patients have shown diminished or loss of
response to infliximab, owing to the development of anti-
bodies directed against the drug. Thus, new biological agents
should be developed and used for the treatment of UC. In our
study, adalimumab and golimumab have also been found to
be effective in UC, because they are capable of inducing
response, remission, and even mucosal healing.
In conclusion, our study suggested that TNF-a blockers
were superior to controls in achieving short-term clinical
response/remission, long-term remission, and mucosal
healing, and decreased the colectomy rate and serious
adverse reactions. Although TNF-a blockers were largely
safe, it is important to understand that serious adverse
events were probably associated with anti-TNF-a therapies.
Because anti-TNF-a therapies are nonselective, a new tech-
nology can be exploited for selective detection as well as
noninvasive therapy of UC. Nanomedicine is one of the most
rapidly developing fields in the 21st century [35]. It has the
ability for highly selective accumulation in the diseased tis-
sue and is capable of delivering an effective therapeutic ac-
tion selectively. Thus, we believe nanomedicine combined
with anti-TNF-a therapies will lead breakthroughs for the
treatment of UC.
Owing to the limitations of this meta-analysis, more pro-
spective randomized trials are needed to confirm the results.Conflicts of interest
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